Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia.
Aoki Y, Takaesu Y, Matsui K, Tokumasu T, Tani H, Takekita Y, Kanazawa T, Kishimoto T, Tarutani S, Hashimoto N, Takeuchi H, Mishima K, Inada K. Aoki Y, et al. Among authors: hashimoto n. Neuropsychopharmacol Rep. 2023 Sep;43(3):391-402. doi: 10.1002/npr2.12366. Epub 2023 Jul 14. Neuropsychopharmacol Rep. 2023. PMID: 37452456 Free PMC article.
Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.
Kusumi I, Arai Y, Okubo R, Honda M, Matsuda Y, Matsuda Y, Tochigi A, Takekita Y, Yamanaka H, Uemura K, Ito K, Tsuchiya K, Yamada J, Yoshimura B, Mitsui N, Matsubara S, Segawa T, Nishi N, Sugawara Y, Kako Y, Shinkawa I, Shinohara K, Konishi A, Iga J, Hashimoto N, Inomata S, Tsukamoto N, Ito H, Ito YM, Sato N. Kusumi I, et al. Among authors: hashimoto n. BJPsych Open. 2018 Oct 30;4(6):454-460. doi: 10.1192/bjo.2018.56. eCollection 2018 Nov. BJPsych Open. 2018. PMID: 30450224 Free PMC article.
Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.
Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H, Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T, Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E, Tomita H, Ohi K, Muraoka H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A, Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga JI, Ichihashi K, Ogasawara K, Yamada H, Inada K, Hashimoto R. Takaesu Y, et al. Among authors: hashimoto n, hashimoto r. Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648. doi: 10.1111/pcn.12911. Epub 2019 Aug 22. Psychiatry Clin Neurosci. 2019. PMID: 31437336 Free PMC article.
Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.
Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, Hashimoto R. Ichihashi K, et al. Among authors: hashimoto n, hashimoto r. Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286. doi: 10.1002/npr2.12122. Epub 2020 Jun 30. Neuropsychopharmacol Rep. 2020. PMID: 32602667 Free PMC article.
Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.
Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, Hashimoto R. Iida H, et al. Among authors: hashimoto n, hashimoto r. Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669. doi: 10.1111/pcn.13143. Epub 2020 Oct 9. Psychiatry Clin Neurosci. 2020. PMID: 32881226 Free PMC article. No abstract available.
Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms.
Takeuchi H, Takekita Y, Hori H, Oya K, Miura I, Hashimoto N, Yasui-Furukori N. Takeuchi H, et al. Among authors: hashimoto n. Hum Psychopharmacol. 2021 Nov;36(6):e2804. doi: 10.1002/hup.2804. Epub 2021 Jul 9. Hum Psychopharmacol. 2021. PMID: 34241916 Free PMC article.
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K, Watanabe K, Shimoda K, Hashimoto R. Hashimoto N, et al. Among authors: hashimoto r. Asian J Psychiatr. 2021 Sep;63:102744. doi: 10.1016/j.ajp.2021.102744. Epub 2021 Jul 15. Asian J Psychiatr. 2021. PMID: 34325252 Free article.
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.
Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga JI, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, Hashimoto R. Yasui-Furukori N, et al. Among authors: hashimoto n, hashimoto r. Neuropsychopharmacol Rep. 2022 Mar;42(1):3-9. doi: 10.1002/npr2.12218. Epub 2021 Dec 2. Neuropsychopharmacol Rep. 2022. PMID: 34854260 Free PMC article.
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.
Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, Hashimoto R. Furihata R, et al. Among authors: hashimoto n, hashimoto r. Sleep Med. 2022 Jan;89:23-30. doi: 10.1016/j.sleep.2021.11.005. Epub 2021 Nov 22. Sleep Med. 2022. PMID: 34875519 Free article.
2,422 results